Brendan P. Eckelman - Mar 8, 2024 Form 4 Insider Report for Inhibrx, Inc. (INBX)

Role: Chief Scientific Officer
Signature: /s/ Kelly D. Deck, as attorney in fact for Brendan P. Eckelman
Stock symbol: INBX
Transactions as of: Mar 8, 2024
Transactions value $: -$1,403,546
Form type: 4
Date filed: 3/12/2024, 06:04 PM
Previous filing: Mar 2, 2023
Next filing: Mar 15, 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	INBX	Stock Option (right to buy)	Options Exercise	-$76.9K	-2.15K	-5.38%	$35.75	37.9K	Mar 8, 2024	Common Stock	2.15K	$33.63	Direct	F1
transaction	INBX	Stock Option (right to buy)	Options Exercise	-$243K	-6.88K	-18.17%	$35.30	31K	Mar 11, 2024	Common Stock	6.88K	$33.63	Direct	F1, F2
transaction	INBX	Stock Option (right to buy)	Options Exercise	-$236K	-6.68K	-16.7%	$35.33	33.3K	Mar 11, 2024	Common Stock	6.68K	$23.30	Direct	F3
transaction	INBX	Stock Option (right to buy)	Options Exercise	-$701K	-19.9K	-64.24%	$35.25	11.1K	Mar 12, 2024	Common Stock	19.9K	$33.63	Direct	F1, F4
transaction	INBX	Stock Option (right to buy)	Options Exercise	-$146K	-4.15K	-12.46%	$35.25	29.2K	Mar 12, 2024	Common Stock	4.15K	$23.30	Direct	F3, F5

Showing 1 to 5 of 5 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 15, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
F2	The stock options were exercised in multiple transactions at prices ranging from $35.2927 to $35.3104, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F3	Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 3, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
F4	The stock options were exercised in multiple transactions at prices ranging from $35.25 to $35.325, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F5	The stock options were exercised in multiple transactions at prices ranging from $35.25 to $35.27, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.